No Data
Bullish raid! The Hong Kong stock market's pharmaceutical Sector has surged across the board. How will it develop in the future?
Super track explosion.
With continued decrease in volume and fluctuations, the market may face a choice of direction. Can innovative drugs and AI bear the banner of counterattack?
Track the entire lifecycle of the main Sector.
Highlights from the brokerage morning meeting: It is expected that this year's key vaccine varieties will likely resume sales growth trends under a low base.
In today's brokerage morning meeting, GUOTAI HAITONG SEC believes that the coal Industry has fully released risks, and an upward trend can be expected; Zhongtai stated that the Sector is expected to gradually recover, and continuous attention should be paid to clinical CRO investment opportunities; China Securities Co.,Ltd. pointed out that this year's major vaccine varieties are expected to restore the sales growth trend due to a low base.
The concepts of new consumption and mergers and acquisitions remain hot! Grasping the rotation opportunities with the continuous warming of short-term sentiment may be the key.
Yesterday, the overall market continued its fluctuating and differentiated trend, with short-term speculative sentiment warming up persistently, and both the North Securities 50 and the Micro-Plate stock Index reached new historical highs.
Hong Kong stock pharmaceutical stocks are all performing strongly, with the Yinhua CSI Innovative Drugs Industry ETF, Hwabao WP CSI Medical Service ETF, and CSI Health Care ETF experiencing a surge.
Hong Kong pharmaceutical stocks rose across the board, with 3SBIO surging over 35%, ZHAOKE OPHTH-B rising more than 13%, and CSPC PHARMA increasing by 7%.
Treatment similar to Coal Industrial Concept(coal Industry)! The discount on American biopharmaceutical stocks is nearing an extreme value, and a series of major events is upcoming.
A recent series of events has intensified the volatility of the U.S. pharmaceutical Sector, with the biopharmaceutical Industry's PE discount relative to the S&P 500 at one point widening to extremes seen during the global financial crisis and the peak of the COVID-19 pandemic. Goldman Sachs bluntly stated that the current Trade status of the pharmaceutical Industry is akin to energy stocks at the peak of the ESG craze—almost like a dying Industry.
